Cargando…

Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor

Adenosine triphosphate (ATP)-sensitive potassium (K(ATP)) channels in pancreatic β-cells play a crucial role in insulin secretion and glucose homeostasis. These channels are composed of two subunits: a pore-forming subunit (Kir6.2) and a regulatory subunit (sulphonylurea receptor-1). Recent studies...

Descripción completa

Detalles Bibliográficos
Autor principal:	Proks, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689011/ https://www.ncbi.nlm.nih.gov/pubmed/23807917 http://dx.doi.org/10.4093/dmj.2013.37.3.157

Ejemplares similares

Molecular Mechanism of Sulphonylurea Block of K(ATP) Channels Carrying Mutations That Impair ATP Inhibition and Cause Neonatal Diabetes
por: Proks, Peter, et al.
Publicado: (2013)

Binding of sulphonylureas to plasma proteins – A K(ATP) channel perspective
por: Proks, Peter, et al.
Publicado: (2018)

Molecular action of sulphonylureas on K(ATP) channels: a real partnership between drugs and nucleotides
por: de Wet, Heidi, et al.
Publicado: (2015)

A Mouse Model of Human Hyperinsulinism Produced by the E1506K Mutation in the Sulphonylurea Receptor SUR1
por: Shimomura, Kenju, et al.
Publicado: (2013)

First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment
por: Ioacara, Sorin, et al.
Publicado: (2017)

Optimal utilisation of sulphonylureas in resource-constrained settings
por: Naidoo, Poobalan, et al.
Publicado: (2014)

Switching to Sulphonylureas in Children With iDEND Syndrome Caused by KCNJ11 Mutations Results in Improved Cerebellar Perfusion
por: Fendler, Wojciech, et al.
Publicado: (2013)

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
por: Chacra, A R, et al.
Publicado: (2009)

What’s next after metformin? focus on sulphonylurea: add-on or combination therapy
por: Lim, Phei C., et al.
Publicado: (2015)

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
por: van Dalem, Judith, et al.
Publicado: (2016)

Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk
por: Vedovato, Natascia, et al.
Publicado: (2016)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Variation in KCNQ1 is associated with therapeutic response to sulphonylureas
por: Schroner, Zbynek, et al.
Publicado: (2011)

Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care
por: Orsini Federici, Marco, et al.
Publicado: (2021)

Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study
por: Wilke, Thomas, et al.
Publicado: (2016)

Successful transition from insulin to sulphonylurea in a child with neonatal diabetes mellitus diagnosed beyond six months of age due to C42R mutation in the KCNJ11 gene
por: Poon, Sarah Wing-yiu, et al.
Publicado: (2022)

Phenotype of a transient neonatal diabetes point mutation (SUR1-R1183W) in mice
por: Sachse, Gregor, et al.
Publicado: (2021)

Sulphonylurea Usage in Melioidosis Is Associated with Severe Disease and Suppressed Immune Response
por: Liu, Xiang, et al.
Publicado: (2014)

Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
por: John, Mathew, et al.
Publicado: (2020)

Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis
por: McIntosh, Brendan, et al.
Publicado: (2012)

The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study
por: Al-Arouj, M, et al.
Publicado: (2013)

Molecular Classification of Pesticides Including Persistent Organic Pollutants, Phenylurea and Sulphonylurea Herbicides
por: Torrens, Francisco, et al.
Publicado: (2014)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations
por: Sarnobat, D., et al.
Publicado: (2021)

Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register
por: Lim, Lee‐Ling, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
por: Degli Esposti, Luca, et al.
Publicado: (2014)

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy
por: Inzucchi, S. E., et al.
Publicado: (2015)

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin
por: Seino, Y, et al.
Publicado: (2014)

Risk of a first‐ever acute myocardial infarction and all‐cause mortality with sulphonylurea treatment: A population‐based cohort study
por: van Dalem, Judith, et al.
Publicado: (2017)

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
por: Al Sifri, S, et al.
Publicado: (2011)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
por: Fournier, Marie, et al.
Publicado: (2014)

Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial
por: Azar, S. T., et al.
Publicado: (2016)

Single Nucleotide Polymorphisms Associated with Metformin and Sulphonylureas’ Glycaemic Response among South African Adults with Type 2 Diabetes Mellitus
por: Masilela, Charity, et al.
Publicado: (2021)

Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice
por: Bazo-Alvarez, Juan Carlos, et al.
Publicado: (2021)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
por: Salvo, Francesco, et al.
Publicado: (2016)

The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment
por: Klen, Jasna, et al.
Publicado: (2014)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives
por: Martono, Doti P., et al.
Publicado: (2019)

The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2-W68G mutation
por: O'Connell, Susan M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6po92jtduacc9kvnecmnibddpe